Skip to main content
Erschienen in: Heart and Vessels 1/2017

11.07.2016 | Original Article

Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation

verfasst von: Akira Satoh, Shinichi Niwano, Hiroe Niwano, Jun Kishihara, Yuya Aoyama, Jun Oikawa, Hidehira Fukaya, Hideaki Tamaki, Junya Ako

Erschienen in: Heart and Vessels | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Aliskiren, a direct renin inhibitor is expected to achieve sufficient suppression of renin–angiotensin system. We evaluated the effect of aliskiren on the electrical and structural remodeling in a canine atrial fibrillation (AF) model. Twenty-eight dogs were divided into three groups: (1) pacing control group (n = 12), with continuous atrial rapid pacing for 3 or 6 weeks, (2) pacing + aliskiren group (n = 12), with oral aliskiren (30 mg/kg/day), and (3) sham group (n = 4), no pacing nor drug administration. Electrophysiological properties and AF inducibility were evaluated every week. After the protocol, the left atrial tissue was sampled for the further histological and mRNA analysis. The electrical remodeling, AF inducibility, the left atrial enlargement and interstitial fibrosis were observed in pacing control group and were more prominent in the 6-week protocol (vs. 3 week, p < 0.05). The mRNA expressions of matricellular proteins exhibited upregulation in 3-week pacing control, but these upregulations became insignificant in 6 weeks. In contrast, collagen type 3 exhibited significant upregulation in 6 week but not in 3-week protocol. These changes were suppressed in the pacing + aliskiren group. Aliskiren suppressed the atrial remodeling in a canine AF model. This effect was accompanied by the suppression of tissue fibrosis.
Literatur
1.
Zurück zum Zitat Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB (1998) Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 158:229–234CrossRefPubMed Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB (1998) Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 158:229–234CrossRefPubMed
2.
Zurück zum Zitat Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952CrossRefPubMed Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952CrossRefPubMed
3.
Zurück zum Zitat Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925CrossRefPubMed Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:2920–2925CrossRefPubMed
4.
Zurück zum Zitat Hamatani Y, Iguchi M, Nakamura M, Ohtani R, Yamashita Y, Takagi D, Unoki T, Ishii M, Masunaga N, Ogawa H, Hamatani M, Abe M, Akao M (2015) Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure. Heart Vessels. doi:10.1007/s00380-015-0719-4 Hamatani Y, Iguchi M, Nakamura M, Ohtani R, Yamashita Y, Takagi D, Unoki T, Ishii M, Masunaga N, Ogawa H, Hamatani M, Abe M, Akao M (2015) Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure. Heart Vessels. doi:10.​1007/​s00380-015-0719-4
5.
Zurück zum Zitat Yang YJ, Yuan JQ, Fan CM, Pu JL, Fang PH, Ma J, Guo XY, Li YS (2015) Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of ≤1 and without anticoagulant therapy. Heart Vessels. doi:10.1007/s00380-015-0718-5 Yang YJ, Yuan JQ, Fan CM, Pu JL, Fang PH, Ma J, Guo XY, Li YS (2015) Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of ≤1 and without anticoagulant therapy. Heart Vessels. doi:10.​1007/​s00380-015-0718-5
6.
Zurück zum Zitat Members of the Sicilian Gambit (2001) New approaches to antiarrhythmic therapy. Part I: emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation 104:2865–2873CrossRef Members of the Sicilian Gambit (2001) New approaches to antiarrhythmic therapy. Part I: emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation 104:2865–2873CrossRef
7.
Zurück zum Zitat Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM (2006) The renin–angiotensin system: a therapeutic target in atrial fibrillation. Pacing Clin Electrophysiol 29:1006–1012CrossRefPubMed Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM (2006) The renin–angiotensin system: a therapeutic target in atrial fibrillation. Pacing Clin Electrophysiol 29:1006–1012CrossRefPubMed
8.
Zurück zum Zitat Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010) Prevention of atrial fibrillation by renin–angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299–2307CrossRefPubMed Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010) Prevention of atrial fibrillation by renin–angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299–2307CrossRefPubMed
9.
Zurück zum Zitat Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41:2197–2204CrossRefPubMed Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41:2197–2204CrossRefPubMed
10.
Zurück zum Zitat Kataoka N, Nishida K, Kinoshita K, Sakamoto T, Nakatani Y, Tsujino Y, Mizumaki K, Inoue H, Kinugawa K (2016) Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53. Heart Vessels. doi:10.1007/s00380-016-0853-7 Kataoka N, Nishida K, Kinoshita K, Sakamoto T, Nakatani Y, Tsujino Y, Mizumaki K, Inoue H, Kinugawa K (2016) Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53. Heart Vessels. doi:10.​1007/​s00380-016-0853-7
11.
Zurück zum Zitat GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617CrossRef GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617CrossRef
12.
Zurück zum Zitat The AFFIRM Investigators, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833CrossRef The AFFIRM Investigators, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833CrossRef
13.
Zurück zum Zitat J-RHYTHM II Investigators, Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S (2011) Randomized trial of angiotensin II-receptor blocker vs. dihydropyridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace 13:473–479CrossRef J-RHYTHM II Investigators, Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S (2011) Randomized trial of angiotensin II-receptor blocker vs. dihydropyridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace 13:473–479CrossRef
14.
Zurück zum Zitat McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100:1056–1064CrossRefPubMed McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100:1056–1064CrossRefPubMed
15.
Zurück zum Zitat Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47:1936–1939CrossRefPubMed Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47:1936–1939CrossRefPubMed
16.
Zurück zum Zitat Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, Bonizzato A, Graziani M, Anker SD, Coats AJ, Zardini P (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37:1808–1812CrossRefPubMed Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, Bonizzato A, Graziani M, Anker SD, Coats AJ, Zardini P (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37:1808–1812CrossRefPubMed
17.
Zurück zum Zitat MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82:57–61CrossRefPubMedPubMedCentral MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82:57–61CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Baker KM, Kumar R (2006) Intracellular angiotensin II induces cell proliferation independent of AT1 receptor. Am J Physiol Cell Physiol 291:C995–C1001CrossRefPubMed Baker KM, Kumar R (2006) Intracellular angiotensin II induces cell proliferation independent of AT1 receptor. Am J Physiol Cell Physiol 291:C995–C1001CrossRefPubMed
19.
Zurück zum Zitat Re RN (2003) Intracellular renin and the nature of intracrine enzymes. Hypertension 42:117–122CrossRefPubMed Re RN (2003) Intracellular renin and the nature of intracrine enzymes. Hypertension 42:117–122CrossRefPubMed
20.
Zurück zum Zitat Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC (2012) Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol 302:R518–R530CrossRefPubMed Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC (2012) Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol 302:R518–R530CrossRefPubMed
21.
Zurück zum Zitat Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II Suppression in humans by the orally active renin inhibitor aliskiren (SPP100) comparison with enalapril. Hypertension 39(1):E1–E8CrossRefPubMed Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II Suppression in humans by the orally active renin inhibitor aliskiren (SPP100) comparison with enalapril. Hypertension 39(1):E1–E8CrossRefPubMed
22.
Zurück zum Zitat Kojima Jisho, Niwano Shinichi, Moriguchi Masahiko, Ikeda Kazuko, Inuo Kimiatsu, Saito Junko, Izumi Toru (2003) Effect of pilsicainide on atrial electrophysiologic properties in the canine rapid atrial stimulation model. Circ J 67:340–346CrossRefPubMed Kojima Jisho, Niwano Shinichi, Moriguchi Masahiko, Ikeda Kazuko, Inuo Kimiatsu, Saito Junko, Izumi Toru (2003) Effect of pilsicainide on atrial electrophysiologic properties in the canine rapid atrial stimulation model. Circ J 67:340–346CrossRefPubMed
23.
Zurück zum Zitat Sato Daisuke, Niwano Shinichi, Imaki Ryuta, Masaki Yoshihiko, Sasaki Sae, Yuge Masaru, Hirasawa Shoji, Sasaki Takeshi, Moriguchi Masahiko, Niwano Hiroe, Yoshimura Hirokuni, Izumi Tohru (2006) Bepridil inhibits sub-acute phase of atrial electrical remodeling in canine rapid atrial stimulation model. Circ J 70:206–213CrossRefPubMed Sato Daisuke, Niwano Shinichi, Imaki Ryuta, Masaki Yoshihiko, Sasaki Sae, Yuge Masaru, Hirasawa Shoji, Sasaki Takeshi, Moriguchi Masahiko, Niwano Hiroe, Yoshimura Hirokuni, Izumi Tohru (2006) Bepridil inhibits sub-acute phase of atrial electrical remodeling in canine rapid atrial stimulation model. Circ J 70:206–213CrossRefPubMed
24.
Zurück zum Zitat Fukaya H, Niwano S, Niwano H, Masaki Y, Kiryu M, Hirasawa S, Sato D, Moriguchi M, Izumi T (2012) Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model. Int J Cardiol 157:197–206CrossRefPubMed Fukaya H, Niwano S, Niwano H, Masaki Y, Kiryu M, Hirasawa S, Sato D, Moriguchi M, Izumi T (2012) Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model. Int J Cardiol 157:197–206CrossRefPubMed
25.
Zurück zum Zitat Fukaya H, Niwano S, Satoh D, Masaki Y, Niwano H, Kojima J, Moriguchi M, Izumi T (2008) Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. Circ J 72:318–326CrossRefPubMed Fukaya H, Niwano S, Satoh D, Masaki Y, Niwano H, Kojima J, Moriguchi M, Izumi T (2008) Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. Circ J 72:318–326CrossRefPubMed
26.
Zurück zum Zitat Nakashima H, Kumagai K (2007) Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 71:1977–1982CrossRefPubMed Nakashima H, Kumagai K (2007) Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 71:1977–1982CrossRefPubMed
27.
Zurück zum Zitat Zhao Z, Wang X, Li J, Yang W, Cheng L, Chen Y, Liu T, Liu E, Chen K, Li G (2014) Protective effects of aliskiren on atrial ionic remodeling in a canine model of rapid atrial pacing. Cardiovasc Drugs Ther 28(2):137–143CrossRefPubMed Zhao Z, Wang X, Li J, Yang W, Cheng L, Chen Y, Liu T, Liu E, Chen K, Li G (2014) Protective effects of aliskiren on atrial ionic remodeling in a canine model of rapid atrial pacing. Cardiovasc Drugs Ther 28(2):137–143CrossRefPubMed
28.
Zurück zum Zitat De Mello W, Rivera M, Rabell A, Gerena Y (2013) Aliskiren, at low doses, reduces the electrical remodeling in the heart of the TGR(mRen2)27 rat independently of blood pressure. J Renin Angiotensin Aldosterone Syst 14:23–33CrossRefPubMed De Mello W, Rivera M, Rabell A, Gerena Y (2013) Aliskiren, at low doses, reduces the electrical remodeling in the heart of the TGR(mRen2)27 rat independently of blood pressure. J Renin Angiotensin Aldosterone Syst 14:23–33CrossRefPubMed
29.
Zurück zum Zitat Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG, Peters JH, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP (2011) Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res 108:582–592CrossRefPubMed Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG, Peters JH, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP (2011) Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res 108:582–592CrossRefPubMed
30.
Zurück zum Zitat Choi MG, Hynes RO (1979) Biosynthesis and processing of fibronectin in NIL.8 hamster cells. J Biol Chem 254:12050–12055PubMed Choi MG, Hynes RO (1979) Biosynthesis and processing of fibronectin in NIL.8 hamster cells. J Biol Chem 254:12050–12055PubMed
31.
Zurück zum Zitat Singh VP, Le B, Khode R, Baker KM, Kumar R (2008) Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 57:3297–3306CrossRefPubMedPubMedCentral Singh VP, Le B, Khode R, Baker KM, Kumar R (2008) Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 57:3297–3306CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Tsai CF, Chen YC, Lin YK, Chen SA, Chen YJ (2011) Electromechanical effects of the direct renin inhibitor (aliskiren) on the pulmonary vein and atrium. Basic Res Cardiol 106:979–993CrossRefPubMed Tsai CF, Chen YC, Lin YK, Chen SA, Chen YJ (2011) Electromechanical effects of the direct renin inhibitor (aliskiren) on the pulmonary vein and atrium. Basic Res Cardiol 106:979–993CrossRefPubMed
Metadaten
Titel
Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation
verfasst von
Akira Satoh
Shinichi Niwano
Hiroe Niwano
Jun Kishihara
Yuya Aoyama
Jun Oikawa
Hidehira Fukaya
Hideaki Tamaki
Junya Ako
Publikationsdatum
11.07.2016
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 1/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0874-2

Weitere Artikel der Ausgabe 1/2017

Heart and Vessels 1/2017 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.